ANALYSIS OF THE RANGE OF DRUGS USED FOR URILOSIS DISEASE ON THE PHARMACEUTICAL MARKET OF THE REPUBLIC OF UZBEKISTAN
Keywords:
Kidney stones, sodium citrate, potassium bicarbonate, citric acid, uric acid, salts, metabolic diseases, crystalluria.Abstract
Nephrolithiasis is a urological disorder characterized by the formation of calculi (kidney stones) in the renal and urinary tract. This study examines the composition, availability, dosage forms, and cost analysis of nephrolithiasis medications in [Country Name] through a systematic review. The market share of foreign medications declined from 58.34% to 42.85%, while domestic pharmaceutical manufacturers increased their share from 25% to 28.57%, and CIS-based manufacturers from 16.67% to 28.57%. However, the total volume of available medications remained relatively stable. Tablets and capsules account for 33.3% of the total nephrolithiasis medications, all of which are produced by foreign or CIS-based manufacturers.
References
Sofia, N. H., & Walter, T. M. (2016). Prevalence and risk factors of kidney stone.Global Journal for Research Analysis.2.Ferraro, P. M., Ferraro, P. M., Ferraro, P. M., Robertson, W. G., Robertson, W. G., Robertson, W. G., Unwin, R., Unwin, R., & Unwin, R. (2007). Renal stone disease.Medicine. https://doi.org/10.1016/J.MPMED.2015.05.003
Zanni, G. R. (2009). Kidney stones: painful and common--but preventable. The Consultant Pharmacist : The Journal of the American Society of Consultant Pharmacists. https://doi.org/10.4140/TCP.N.2009.338
Peerapen P, Thongboonkerd V. Kidney Stone Prevention. Adv Nutr. 2023 May;14(3):555-569. doi: 0.1016/j.advnut.2023.03.002. Epub 2023 Mar 9. PMID: 36906146; PMCID: PMC10201681.
Kartha G, Calle JC, Marchini GS, Monga M. Impact of stone disease: chronic kidney disease and quality of life. Urol Clin North Am. 2013 Feb;40(1):135-47. doi: 10.1016/j.ucl.2012.09.004. Epub 2012 Oct 23. PMID: 23177641.
Wang Z, Zhang Y, Zhang J, Deng Q, Liang H. Recent advances on the mechanisms of kidney stone formation (Review). Int J Mol Med. 2021 Aug;48(2):149. doi: 10.3892/ijmm.2021.4982. Epub 2021 Jun PMID: 34132361; PMCID: PMC8208620.
Konstantinova OV, Yanenko EK. [EXPERIENCE OF USE OF BLEMAREN® IN THE TREATMENT OF PATIENTS IN URIC ACID AND CALCIUM OXALATE UROLITHIASIS]. Urologiia. 2015 Sep-Oct;(5):22-4, Russian. PMID: 26859932.
Goswami, P. K. (2014). Urolithiasis: An Overview.International Journal of Pharmaceutical & Biological Archive.
Tyagi, S. (2012). Review on Kidney Stones.Journal of Biomedical and Pharmaceutical Research.
